PRESS RELEASE | Basel, Switzerland, November 4, 2021

Versameb to present novel data on its lead asset, VMB-100 at 9^th International mRNA Health Conference

• VMB-100 shows therapeutic potential in Stress Urinary Incontinence
• RNA engineering technology enhances the potency of mRNA

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces that its Chief Scientific Officer, Friedrich Metzger, will be presenting data on its mRNA engineering technology and lead therapeutic candidate, VMB-100, at the 9th International mRNA Health Conference taking place on 9^th and 10^th November 2021 in Berlin.

Versameb has developed a groundbreaking RNA technology platform, VERSagile, and is building a pipeline of promising first-in-class RNA therapeutics. VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter.

Friedrich Metzger, Chief Scientific Officer, said: “Our findings indicate that local injection of our engineered mRNA results in therapeutically relevant target protein expression and secretion in muscle tissue, leading to muscle tissue regeneration. The regenerative effects seen following a single local injection support its therapeutic potential in muscle-related disorders such as stress urinary incontinence through restoration of muscle function.”

Presentation title: Regeneration of muscle tissue and function in Stress Urinary Incontinence using engineered RNA
Authors: Friedrich Metzger, Justin Antony Selvaraj, Claudia Bohnert, Nicole Stiffler, Pascale Birrer, Sina Zimmerli, Isabelle Kappeler, Tatsuo Satoh, Petra Hillmann, Isabel Ferreira, Klaas Zuideveld
Date & Time: Wednesday, 10 November, 10:40am – 10:55am CET during Session V: Therapeutics

Up to 50% of adult women suffer from SUI with no drug treatment currently approved. While behavioral and surgical interventions do exist, most are not effective in the long term.

Klaas Zuideveld, Chief Executive Officer, said: “We are delighted to be presenting our findings at this prestigious conference. In the past year, the tremendous potential of mRNA has been shown through the COVID-19 vaccines. Versameb’s VERSagile platform has the potential to yield first-in-class RNA therapeutics for disease indications with high unmet need.”

Contact for media enquiries:

Versameb
Dr Klaas Zuideveld, CEO
ir@versameb.com

Optimum Strategic Communications
Mary Clark, Stella Lempidaki, Zoe Bolt
Tel: +44 (0)20 3882 9621
versameb@optimumcomms.com

DOWNLOAD PDF
– English